Notes on Gender Dysphoria: Non-Surgical and Surgical Treatments
Definition and Prevalence
Gender dysphoria (also called gender incongruence) is defined as severe or persistent distress due to incongruence between one’s gender identity and biological sex.
Prevalence estimates:
Approximately 1.4\,\text{million} Americans identify as transgender; about 25\,\text{million} people worldwide.
The prevalence in the U.S. is around 0.6\%, though this varies by definition and geography.
When broken down by state, prevalence ranges around 0.3\% - 0.76\%.
The pathophysiology is multifactorial and not fully understood. Contributing factors include:
Genetics and prenatal hormone exposure; twin studies show genetic components and heritability estimates vary but are substantial.
Neuroanatomical differences and brain connectivity patterns that align more with identified gender than with assigned birth sex.
History of trauma and psychosocial factors may modulate risk.
Typical presentation timing:
Most commonly in early adolescence, but can present in early childhood or after age 18.
Comorbidity:
Anxiety and depression are the most common co-occurring conditions and may drive help-seeking.
Diagnosis and management are individualized and not fully understood; treatments range from psychosocial support to hormonal therapy and gender-affirming surgeries.
Epidemiology
Global estimate: about 25\,\text{million} transgender individuals worldwide.
Prevalence varies with definition and geography; self-identification tends to exceed treatment-seeking prevalence.
In the U.S., prevalence estimates are around 0.6\% with regional variation; similar variability exists across countries.
Recent data show increases in the number of individuals seeking treatment for gender dysphoria, with the largest rise among children and adolescents.
Sex ratio shifts over time: historical bias toward birth-assigned males has shifted toward birth-assigned females in some cohorts.
Typical age of onset and seeking treatment:
First symptoms often by age ~7, with many living 20+ years before seeking treatment.
References to larger epidemiological trends emphasize variability based on definitions and access to care.
Pathophysiology and Risk Factors
Biological basis supported by converging lines of evidence:
Genetic links: sex hormone signaling genes show differential patterns in transgender individuals; twin studies suggest heritability with many small studies indicating genetic contribution.
Neuroanatomical differences: transgender individuals often show brain structure and connectivity that align with identified gender; cortical thickness and connectivity in relevant networks differ versus birth-assigned gender.
Prenatal androgen exposure: high androgen exposure (e.g., CAH) correlates with gender dissatisfaction in some cases; complete androgen insensitivity syndrome (CAIS) associates with female gender identity despite XY karyotype.
Specific conditions:
CAH (congenital adrenal hyperplasia) linked to increased likelihood of gender incongruence in those with elevated prenatal androgens.
CAIS (complete androgen insensitivity syndrome) associated with female gender identification due to androgen resistance despite XY chromosomes.
Psychosocial factors:
Earlier hypotheses about parental influence (e.g., paternal absence) are less supported; more recent data suggest higher parental psychopathology and childhood anxiety increase risk.
Child trauma history is common in those with gender dysphoria and can influence attachment patterns and coping strategies.
Overall interpretation: brain development and biology appear to play important roles in gender identity, with psychosocial context shaping presentation and coping.
Clinical Presentation and Diagnosis
Presentation: increasing recognition and earlier treatment over the last two decades; adolescents commonly present with incongruence between birth sex and gender identity.
Comorbidity and risk factors:
Higher rates of anxiety and depression; suicidality risk is elevated if untreated but can be reduced with gender-affirming care.
History of childhood trauma is more prevalent in this population and is linked to later presentation and dissociative coping.
Age at presentation:
Common in adolescence but can occur in early adulthood; many individuals report family or peer pressures delaying presentation.
Diagnostic framework:
DSM-5 criteria for adolescents require two of the following with at least 6 months duration and clinically significant distress or impairment (A criterion plus 2+ symptoms):
1) A marked incongruence between experienced/expressed gender and primary/secondary sex characteristics (or anticipated secondary characteristics in younger adolescents).
2) A strong desire to be rid of one’s primary/secondary sex characteristics because of incongruence with experienced/expressed gender.
3) A strong desire for the primary/secondary sex characteristics of the other gender.
4) A strong desire to be of the other gender (or another gender different from assigned gender).
5) A strong desire to be treated as the other gender (or alternative gender).
6) A strong conviction that one has the typical feelings/reactions of the other gender (or alternative).
Assessment tools and screening:
GIDYQ-AA (Gender Identity/Gender Dysphoria Questionnaire for Adolescents and Adults): sensitivity 90.4\%, specificity 99.7\% in validation samples.
GAD-7 and PHQ-9 recommended for adolescents, due to high rates of anxiety/depression.
Gender Identity Reflection and Rumination Scale: higher scores correlate with more frequent thoughts about gender identity and greater dysphoria.
Community belonging and acceptance correlate with lower anxiety/depression and suicidality.
Diagnostic and care framework:
World Professional Association for Transgender Health (WPATH) Standards of Care provide flexible guidelines to accommodate individual goals and needs.
Emphasizes a multidisciplinary approach and individualized treatment planning.
Diagnosis is validated through clinical history and validated questionnaires; ongoing psychosocial assessment is important.
Treatment Overview
Two primary treatment categories: non-operative and operative.
Treatment is flexible and individualized, often combining modalities across disciplines.
WPATH standards support a staged approach, generally favoring social transition and hormone therapy prior to genital surgery, though not all procedures require all steps.
Key prerequisite considerations for surgery include: multiple referrals, stability on hormone therapy (often at least 12 months), and alignment of goals with patient’s well-being.
Overall aim: reduce distress, improve quality of life, and align physical characteristics with gender identity while minimizing treatment-related morbidity.
NON-OPERATIVE TREATMENT: PSYCHOSOCIAL THERAPY
First-line non-operative option:
Psychosocial therapy and counseling to improve quality of life through open communication and social transition.
Goals of therapy:
Support patients in implementing gender identity with family, friends, and society.
Guidance on coming out and body image in relation to gender norms.
Benefits and accessibility:
Ongoing/long-term support, not a one-time intervention; supports can be lifelong.
Access to peer groups and internet-based supports when professional psychotherapy is unavailable.
Role of WPATH:
Therapy can be effective without hormone therapy or gender-affirming surgery.
NON-OPERATIVE TREATMENT: HORMONE REPLACEMENT THERAPY (HRT)
General framework:
Multiple hormone regimens exist; there is no universally accepted standard regimen.
Requires comprehensive pre-treatment work-up: risk screening, medical history, exams, and laboratory assessments to ensure safety.
Written indication for HRT should be established by a psychotherapist or psychiatrist to confirm the diagnosis.
Goals of HRT:
Promote characteristics of the desired gender while minimizing characteristics of biological sex.
Feminizing therapy for male-to-female (MTF):
Effects include skin softening, reduced body hair, decreased muscle mass, reduced testicular size, and breast development.
Onset may begin within 6\text{ months}; maximum effects in 1-2\text{ years}.
Typically involves physiologic estrogen plus anti-androgen therapy; estrogen alone is often insufficient to suppress testosterone to female levels.
Estrogen: physiologic 17β-estradiol via oral or transdermal routes.
Anti-androgen: spironolactone (androgen receptor antagonism; some estrogenic activity).
Monitoring: serum estradiol levels regularly every 3\text{ months}; risks include liver disease, cardiovascular disease, hypertension, hyperprolactinemia, hypertriglyceridemia, and thromboembolic events.
Masculinizing therapy for female-to-male (FTM):
Primary hormone: testosterone (e.g., testosterone enanthate, testosterone cypionate; IM injections; alternative options include transdermal gels/patches).
Effects include increased skin oiliness, facial/body hair, muscle mass/strength, fat redistribution, cessation of menses, deepened voice, enlarged clitoris, and vaginal atrophy.
Anti-estrogen therapy is not required to achieve physiologic testosterone levels.
Monitoring: risks include erythrocytosis, liver dysfunction, cerebrovascular disease, coronary artery disease, and breast/uterine cancer; regular monitoring is advised.
Overall considerations:
Pre-treatment assessment screens for cardiovascular risk and thromboembolism; ongoing surveillance for treatment-related adverse effects.
OPERATIVE TREATMENT
General principle:
Many patients pursue gender-confirming surgery (GCS) to achieve desired body image and gender identity; procedures span genital and non-genital surgeries.
GCS is typically considered after psychosocial therapy and HRT, and often after social transition; however, not all procedures require prior steps.
WPATH criteria for genital GCS commonly include at least 2 referrals from separate medical professionals and at least 12 months of continued HRT.
Multidisciplinary execution:
Genital and non-genital surgeries are performed across specialties (plastic surgery, urology, otolaryngology, gynecology, general surgery).
NON-GENITAL FEMINIZATION (transgender women):
Procedures include hair reconstruction/removal, voice modification, lipofilling, botulinum toxin injections, mammoplasty/breast augmentation, gluteal augmentation, waist lipoplasty, and facial plastics.
Facial plastic options: lip filler, rhytidectomy (face lifts), rhinoplasty, sinus surgery, brow/forehead work (supraorbital ridge reduction), mandibular/genioplasty.
High patient satisfaction reported for non-genital feminization procedures; often preferred to genital reconstruction when aligned with goals.
GENITAL FEMINIZATION (MTF):
Choice depends on whether penetrative ability is desired:
Orchiectomy + penectomy + urethroplasty for feminized appearance without penetrative ability.
Vulvoplasty with clitoro-labioplasty for a natural-looking vulva without penetrative capability.
Vaginoplasty (with or without additional procedures) for natural vulva with penetrative ability.
Vagina creation methods: penile skin inversion or intestinal grafts; vulvar shaping with skin grafts.
Common complications: neovaginal bleeding, discharge, introital stenosis, misdirected urinary stream, urinary incontinence, wound-healing disorders, infection.
GENITAL MASCULINIZATION (trans men):
Non-genital masculinization options emphasize chest masculinization (subcutaneous mastectomy, chest contouring, pectoral implants, breast augmentation) and facial masculinization (genioplasty, liposuction, facial hair transplantation).
Genital masculinization options include removal of reproductive organs (hysterectomy, oophorectomy, vaginectomy), urethral lengthening for standing micturition, metoidioplasty, phalloplasty with scrotoplasty.
As with feminization, genital masculinization carries risks such as urinary incontinence, wound-healing disorders, and infection.
Outcomes and Prognosis
Benefits of gender-affirming care include reduced suicidality and improved quality of life.
Earlier treatment (e.g., at younger ages) associated with lower suicidality; ongoing research supports improved psychosocial outcomes with comprehensive care.
Non-surgical and surgical options have high satisfaction rates when aligned with patient goals and supported by HRT.
Acknowledge ongoing gaps: need for large, long-term studies on health outcomes after medical and/or surgical treatment for gender dysphoria.
Conclusion and Practical Implications
Shifts in societal acceptance have increased open expression of gender diversity.
Evidence supports a biological basis for gender identity with ongoing investigation into mechanisms.
Clinicians should adopt a patient-centered, multidisciplinary approach, balancing psychosocial support, hormone therapy, and surgical options.
Clinicians should discuss ethical, psychosocial, and practical implications of care, including fertility considerations and potential risks.
Future research should focus on long-term outcomes and optimization of multidisciplinary pathways to care.
Key References and Tools Mentioned
GIDYQ-AA: sensitivity 90.4\%, specificity 99.7\% for identifying gender dysphoria.
GAD-7 and PHQ-9 recommended for adolescents with gender dysphoria.
WPATH Standards of Care emphasize flexible, individualized care and staged treatment approaches; social transition and HRT often precede genital surgery but are not strictly required for all procedures.
Enduring clinical tools include the Gender Identity Reflection and Rumination Scale and community belonging measures, which relate to mental health outcomes.
Hormone therapy guidelines emphasize monitoring and risk management; and cross-disciplinary collaboration in decision-making for surgical pathways.
Definition and Prevalence
Gender dysphoria (also called gender incongruence) is defined as severe or persistent distress due to incongruence between one’s gender identity and biological sex.
Prevalence estimates:
Approximately 1.4\ \text{million} Americans identify as transgender; about 25\ \text{million} people worldwide.
The prevalence in the U.S. is around 0.6\%, though this varies by definition and geography.
When broken down by state, prevalence ranges around 0.3\% - 0.76\%.
The pathophysiology is multifactorial and not fully understood. Contributing factors include:
Genetics and prenatal hormone exposure; twin studies show genetic components and heritability estimates vary but are substantial.
Neuroanatomical differences and brain connectivity patterns that align more with identified gender than with assigned birth sex.
History of trauma and psychosocial factors may modulate risk.
Typical presentation timing:
Most commonly in early adolescence, but can present in early childhood or after age 18.
Comorbidity:
Anxiety and depression are the most common co-occurring conditions and may drive help-seeking.
Diagnosis and management are individualized and not fully understood; treatments range from psychosocial support to hormonal therapy and gender-affirming surgeries.
Epidemiology
Global estimate: about 25\ \text{million} transgender individuals worldwide.
Prevalence varies with definition and geography; self-identification tends to exceed treatment-seeking prevalence.
In the U.S., prevalence estimates are around 0.6\% with regional variation; similar variability exists across countries.
Recent data show increases in the number of individuals seeking treatment for gender dysphoria, with the largest rise among children and adolescents.
Sex ratio shifts over time: historical bias toward birth-assigned males has shifted toward birth-assigned females in some cohorts.
Typical age of onset and seeking treatment:
First symptoms often by age ~7, with many living 20+ years before seeking treatment.
References to larger epidemiological trends emphasize variability based on definitions and access to care.
Pathophysiology and Risk Factors
Biological basis supported by converging lines of evidence:
Genetic links: sex hormone signaling genes show differential patterns in transgender individuals; twin studies suggest heritability with many small studies indicating genetic contribution.
Neuroanatomical differences: transgender individuals often show brain structure and connectivity that align with identified gender; cortical thickness and connectivity in relevant networks differ versus birth-assigned gender.
Prenatal androgen exposure: high androgen exposure (e.g., CAH) correlates with gender dissatisfaction in some cases; complete androgen insensitivity syndrome (CAIS) associates with female gender identity despite XY karyotype.
Specific conditions:
CAH (congenital adrenal hyperplasia) linked to increased likelihood of gender incongruence in those with elevated prenatal androgens.
CAIS (complete androgen insensitivity syndrome) associated with female gender identification due to androgen resistance despite XY chromosomes.
Psychosocial factors:
Earlier hypotheses about parental influence (e.g., paternal absence) are less supported; more recent data suggest higher parental psychopathology and childhood anxiety increase risk.
Child trauma history is common in those with gender dysphoria and can influence attachment patterns and coping strategies.
Overall interpretation: brain development and biology appear to play important roles in gender identity, with psychosocial context shaping presentation and coping.
Clinical Presentation and Diagnosis
Presentation: increasing recognition and earlier treatment over the last two decades; adolescents commonly present with incongruence between birth sex and gender identity.
Comorbidity and risk factors:
Higher rates of anxiety and depression; suicidality risk is elevated if untreated but can be reduced with gender-affirming care.
History of childhood trauma is more prevalent in this population and is linked to later presentation and dissociative coping.
Age at presentation:
Common in adolescence but can occur in early adulthood; many individuals report family or peer pressures delaying presentation.
Diagnostic framework:
DSM-5 criteria for adolescents require two of the following with at least 6\ \text{months} duration and clinically significant distress or impairment (A criterion plus 2+ symptoms):
1) A marked incongruence between experienced/expressed gender and primary/secondary sex characteristics (or anticipated secondary characteristics in younger adolescents).
2) A strong desire to be rid of one’s primary/secondary sex characteristics because of incongruence with experienced/expressed gender.
3) A strong desire for the primary/secondary sex characteristics of the other gender.
4) A strong desire to be of the other gender (or another gender different from assigned gender).
5) A strong desire to be treated as the other gender (or alternative gender).
6) A strong conviction that one has the typical feelings/reactions of the other gender (or alternative).
Assessment tools and screening:
GIDYQ-AA (Gender Identity/Gender Dysphoria Questionnaire for Adolescents and Adults): sensitivity 90.4\%, specificity 99.7\% in validation samples.
GAD-7 and PHQ-9 recommended for adolescents, due to high rates of anxiety/depression.
Gender Identity Reflection and Rumination Scale: higher scores correlate with more frequent thoughts about gender identity and greater dysphoria.
Community belonging and acceptance correlate with lower anxiety/depression and suicidality.
Diagnostic and care framework:
World Professional Association for Transgender Health (WPATH) Standards of Care provide flexible guidelines to accommodate individual goals and needs.
Emphasizes a multidisciplinary approach and individualized treatment planning.
Diagnosis is validated through clinical history and validated questionnaires; ongoing psychosocial assessment is important.
Treatment Overview
Two primary treatment categories: non-operative and operative.
Treatment is flexible and individualized, often combining modalities across disciplines.
WPATH standards support a staged approach, generally favoring social transition and hormone therapy prior to genital surgery, though not all procedures require all steps.
Key prerequisite considerations for surgery include: multiple referrals, stability on hormone therapy (often at least 12\ \text{months}), and alignment of goals with patient’s well-being.
Overall aim: reduce distress, improve quality of life, and align physical characteristics with gender identity while minimizing treatment-related morbidity.
NON-OPERATIVE TREATMENT: PSYCHOSOCIAL THERAPY
First-line non-operative option:
Psychosocial therapy and counseling to improve quality of life through open communication and social transition.
Goals of therapy:
Support patients in implementing gender identity with family, friends, and society.
Guidance on coming out and body image in relation to gender norms.
Benefits and accessibility:
Ongoing/long-term support, not a one-time intervention; supports can be lifelong.
Access to peer groups and internet-based supports when professional psychotherapy is unavailable.
Role of WPATH:
Therapy can be effective without hormone therapy or gender-affirming surgery.
NON-OPERATIVE TREATMENT: HORMONE REPLACEMENT THERAPY (HRT)
General framework:
Multiple hormone regimens exist; there is no universally accepted standard regimen.
Requires comprehensive pre-treatment work-up: risk screening, medical history, exams, and laboratory assessments to ensure safety.
Written indication for HRT should be established by a psychotherapist or psychiatrist to confirm the diagnosis.
Goals of HRT:
Promote characteristics of the desired gender while minimizing characteristics of biological sex.
Feminizing therapy for male-to-female (MTF):
Effects include skin softening, reduced body hair, decreased muscle mass, reduced testicular size, and breast development.
Onset may begin within 6\ \text{months}; maximum effects in 1-2\ \text{years}.
Typically involves physiologic estrogen plus anti-androgen therapy; estrogen alone is often insufficient to suppress testosterone to female levels.
Estrogen: physiologic 17\beta\text{-estradiol} via oral or transdermal routes.
Anti-androgen: spironolactone (androgen receptor antagonism; some estrogenic activity).
Monitoring: serum estradiol levels regularly every 3\ \text{months}; risks include liver disease, cardiovascular disease, hypertension, hyperprolactinemia, hypertriglyceridemia, and thromboembolic events.
Masculinizing therapy for female-to-male (FTM):
Primary hormone: testosterone (e.g., testosterone enanthate, testosterone cypionate; IM injections; alternative options include transdermal gels/patches).
Effects include increased skin oiliness, facial/body hair, muscle mass/strength, fat redistribution, cessation of menses, deepened voice, enlarged clitoris, and vaginal atrophy.
Anti-estrogen therapy is not required to achieve physiologic testosterone levels.
Monitoring: risks include erythrocytosis, liver dysfunction, cerebrovascular disease, coronary artery disease, and breast/uterine cancer; regular monitoring is advised.
Overall considerations:
Pre-treatment assessment screens for cardiovascular risk and thromboembolism; ongoing surveillance for treatment-related adverse effects.
OPERATIVE TREATMENT
General principle:
Many patients pursue gender-confirming surgery (GCS) to achieve desired body image and gender identity; procedures span genital and non-genital surgeries.
GCS is typically considered after psychosocial therapy and HRT, and often after social transition; however, not all procedures require prior steps.
WPATH criteria for genital GCS commonly include at least 2 referrals from separate medical professionals and at least 12\ \text{months} of continued HRT.
Multidisciplinary execution:
Genital and non-genital surgeries are performed across specialties (plastic surgery, urology, otolaryngology, gynecology, general surgery).
NON-GENITAL FEMINIZATION (transgender women):
Procedures include hair reconstruction/removal, voice modification, lipofilling, botulinum toxin injections, mammoplasty/breast augmentation, gluteal augmentation, waist lipoplasty, and facial plastics.
Facial plastic options: lip filler, rhytidectomy (face lifts), rhinoplasty, sinus surgery, brow/forehead work (supraorbital ridge reduction), mandibular/genioplasty.
High patient satisfaction reported for non-genital feminization procedures; often preferred to genital reconstruction when aligned with goals.
GENITAL FEMINIZATION (MTF):
Choice depends on whether penetrative ability is desired:
Orchiectomy + penectomy + urethroplasty for feminized appearance without penetrative ability.
Vulvoplasty with clitoro-labioplasty for a natural-looking vulva without penetrative capability.
Vaginoplasty (with or without additional procedures) for natural vulva with penetrative ability.
Vagina creation methods: penile skin inversion or intestinal grafts; vulvar shaping with skin grafts.
Common complications: neovaginal bleeding, discharge, introital stenosis, misdirected urinary stream, urinary incontinence, wound-healing disorders, infection.
GENITAL MASCULINIZATION (trans men):
Non-genital masculinization options emphasize chest masculinization (subcutaneous mastectomy, chest contouring, pectoral implants, breast augmentation) and facial masculinization (genioplasty, liposuction, facial hair transplantation).
Genital masculinization options include removal of reproductive organs (hysterectomy, oophorectomy, vaginectomy), urethral lengthening for standing micturition, metoidioplasty, phalloplasty with scrotoplasty.
As with feminization, genital masculinization carries risks such as urinary incontinence, wound-healing disorders, and infection.
Outcomes and Prognosis
Benefits of gender-affirming care include reduced suicidality and improved quality of life.
Earlier treatment (e.g., at younger ages) associated with lower suicidality; ongoing research supports improved psychosocial outcomes with comprehensive care.
Non-surgical and surgical options have high satisfaction rates when aligned with patient goals and supported by HRT.
Acknowledge ongoing gaps: need for large, long-term studies on health outcomes after medical and/or surgical treatment for gender dysphoria.
Conclusion and Practical Implications
Shifts in societal acceptance have increased open expression of gender diversity.
Evidence supports a biological basis for gender identity with ongoing investigation into mechanisms.
Clinicians should adopt a patient-centered, multidisciplinary approach, balancing psychosocial support, hormone therapy, and surgical options.
Clinicians should discuss ethical, psychosocial, and practical implications of care, including fertility considerations and potential risks.
Future research should focus on long-term outcomes and optimization of multidisciplinary pathways to care.
Key References and Tools Mentioned
GIDYQ-AA: sensitivity 90.4\%, specificity 99.7\% for identifying gender dysphoria.
GAD-7 and PHQ-9 recommended for adolescents with gender dysphoria.
WPATH Standards of Care emphasize flexible, individualized care and staged treatment approaches; social transition and HRT often precede genital surgery but are not strictly required for all procedures.
Enduring clinical tools include the Gender Identity Reflection and Rumination Scale and community belonging measures, which relate to mental health outcomes.
Hormone therapy guidelines emphasize monitoring and risk management; and cross-disciplinary collaboration in decision-making for surgical pathways.